[Federal Register Volume 85, Number 170 (Tuesday, September 1, 2020)]
[Notices]
[Pages 54391-54392]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-19220]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Exploring the Roles of Biomolecular

[[Page 54392]]

Condensates (BMCs) in HIV replication, latency, or pathogenesis in 
the context of substance use disorders (R21/R33 Clinical Trial Not 
Allowed).
    Date: September 22, 2020.
    Time: 10:00 a.m. to 11:30 a.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 3 White Flint North, 9th 
Floor, 301 North Stonestreet Avenue, Bethesda, MD 20892, (Virtual 
Meeting).
    Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, Division of Extramural 
Research, National Institute on Drug Abuse, NIH, 3WFN 9th Floor, MSC 
6021, 301 North Stonestreet Avenue, Bethesda, MD 20892, (301) 827-
5843, [email protected]

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel Multi-Site Studies for System-Level Implementation of 
Substance Use Prevention and Treatment Services (R01 and R34).
    Date: September 25, 2020.
    Time: 12:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 3 White Flint North, 9th 
Floor, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Yvonne Owens Ferguson, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, 3WFN 9th 
Floor, MSC 6021, 301 North Stonestreet Avenue, Bethesda, MD 20892, 
(301) 402-7371, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Exploiting Genome or Epigenome Editing to 
Functionally Validate Genes or Variants Involved in Substance Use 
Disorders (R21/R33 Clinical Trial Not Allowed).
    Date: October 15, 2020.
    Time: 1:30 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 3 White Flint North, 9th 
Floor, 301 North Stonestreet Avenue, Bethesda, MD 20892, (Virtual 
Meeting).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, 3WFN 9th 
Floor, MSC 6021, 301 North Stonestreet Avenue, Bethesda, MD 20892, 
(301) 827-4471, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: August 26, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-19220 Filed 8-31-20; 8:45 am]
BILLING CODE 4140-01-P